Phosphorylation of different tau sites during progression of Alzheimer's disease.

Neddens J, Temmel M, Flunkert S, Kerschbaumer B, Hoeller C, Loeffler T, Niederkofler V, Daum G, Attems J, Hutter-Paier B. · 2018

Read Phosphorylation of different tau sites during progression of Alzheimer's disease. by Neddens J, Temmel M, Flunkert S, Kerschbaumer B, Hoeller C, Loeffler T, Niederkofler V, Daum G, Attems J, Hutter-Paier B. (2018) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6027763.txt.

Introduction

Neddens and co-authors track tau changes in Alzheimer's disease. Their research article appeared in Acta Neuropathologica Communications. In this disease, tau protein builds up in tangles. Chemical marks called phosphorylation help drive that build-up. One mark site is already used to stage disease.

The team measured seven mark sites in human brain tissue. Samples came from patients and healthy controls. Automated image analysis kept scoring free of rater bias. Most sites rose only at late disease stages. Two sites rose earlier, in a key relay region. Those sites also showed the largest rise over controls. The authors flag them as possible early targets. Readers get a timed map of tau marks across brain regions.

Catalog record

CREATORNeddens J, Temmel M, Flunkert S, Kerschbaumer B, Hoeller C, Loeffler T, Niederkofler V, Daum G, Attems J, Hutter-Paier B.
YEAR2018
COLLECTIONPAPERS
FORMATTXT
FILE SIZE52 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC6027763

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Phosphorylation of different tau sites during progression of Alzheimer’s disease By Joerg Neddens, Magdalena Temmel, Stefanie Flunkert, Bianca Kerschbaumer, Christina Hoeller, Tina Loeffler, Vera Niederkofler, Guenther Daum, Johannes Attems, Birgit Hutter-Paier Published in: Acta Neuropathologica Communications DOI: 10.1186/s40478-018-0557-6 ABSTRACT Alzheimer’s disease is characterized by accumulation of amyloid plaques and tau aggregates in several cortical brain regions. Tau phosphorylation causes formation of neurofibrillary tangles and neuropil threads. Phosphorylation at tau Ser202/Thr205 is well characterized since labeling of this site is used to assign Braak stage based on occurrence of neurofibrillary tangles. Only little is known about the spatial and temporal phosphorylation profile of other phosphorylated tau (ptau) sites. Here, we investigate total tau and ptau at residues Tyr18, Ser199, Ser202/Thr205, Thr231, Ser262, Ser396, Ser422 as well as amyloid-β plaques in human brain tissue of AD patients and controls. Allo- and isocortical brain regions were evaluated applying rater-independent automated quantification based on digital image analysis. We found that the level of ptau at several residues, like Ser199, Ser202/Thr205, and Ser422 was similar in healthy controls and Braak stages I to IV but was increased in Braak stage V/VI throughout the entire isocortex and transentorhinal cortex. Quantification of ThioS-stained plaques showed a similar pattern. Only tau phosphorylation at Tyr18 and Thr231 was already significantly increased in the transentorhinal region at Braak stage III/IV and hence showed a progressive increase with increasing Braak stages. Additionally, the increase in phosphorylation relative to controls was highest at Tyr18, Thr231 and Ser199. By contrast, Ser396 tau and Ser262 tau showed only a weak phosphorylation in all analyzed brain regions and only minor progression. Our results suggest that the ptau burden in the isocortex is comparable between all analyzed ptau sites when using a quantitative approach while levels of ptau at Tyr18 or Thr231 in the transentorhinal region are different between all Braak stages. Hence these sites could be crucial in the pathogenesis of AD already at early stages and therefore represent putative novel therapeutic targets. Electronic supplementary material The online version of this article (10.1186/s40478-018-0557-6) contains supplementary material, which is available to authorized users. INTRODUCTION Alzheimer’s disease (AD) is neuropathologically characterized by two hallmark lesions, which are extracellular amyloid-β (Aβ) plaques and intracellular accumulations of abnormally phosphorylated tau. Aβ plaques initially develop in neocortical regions and then progress to the limbic system, subcortical nuclei and reach the cerebellum at late stages of the disease [41]. Tau pathology manifests as neurofibrillary tangles (NFTs) and neuropil threads (NTs) and primarily accumulates in the entorhinal region and subsequently progresses to the limbic system and neocortical regions as reflected by NFT Braak stages [8]. Tau aggregation depends on several posttranslational modifications, including but not limited to, truncation, acetylation, ubiquitination, sumoylation and phosphorylation [13, 29, 34]. The best analyzed posttranslational modification in AD is abnormal phosphorylation of tau which in AD is referred to as hyperphosphorylation and that is characterized by an at least 3-fold increase of tau phosphorylation relative to controls. Over 70 potential tau phosphorylation (ptau) sites spanning almost the entire protein structure and including some phosphorylation sites are assumed to be pathologically relevant [40]. Some of these ptau sites are known to be abnormally phosphorylated in paired helical filaments (PHFs), NFTs or NTs during progression of AD but are not phosphorylated in healthy brains [10, 15, 22, 26, 28]. Several of these ptau sites are also phosphorylated in the fetal brain and are thus associated with embryonic brain developmental processes [10, 15, 22]. In the diseased brain, ptau sites are commonly associated with tau aggregation processes such as incomplete binding and destabilization of microtubules, causing the transition from pre-tangles to NFT formation [12, 16, 21, 28, 32]. The temporal and spatial phosphorylation pattern of tau residue Ser202/Thr205 has already been well characterized since staging of AD cases is based on labeling of ptau Ser202/Thr205 using the specific antibody AT8 [1, 9, 20, 46]. However, the phosphorylation profile of other ptau sites known to be involved in AD pathology is so far strongly neglected and analyzed only by ELISA and dot blots of AD brain tissue [20, 46]. Phosphorylation at several residues during disease progression has been repeatedly investigated in tau animal models but barely in AD brain tissue [4, 7, 14, 20, 46]. Hence, the present study aims to evaluate the spatial and temporal phosphorylation profile of different tau sites by applying rater-independent automated quantification based on digital image analysis. We therefore quantified the expression of total tau, amyloid-β plaques and the phosphorylation of seven different tau sites (Tyr18, Ser199, Ser202/Thr205, Thr231, Ser262, Ser396, Ser422) in iso- and allocortical brain regions of AD cases and controls. MATERIALS AND METHODS Human brain samples Paraffin sections of 6 μm thickness and frozen samples from AD patients of three different disease stages [Braak stages I/II, III/IV and V/VI; [9]] and control individuals with Braak stage 0 were provided by the Newcastle Brain Tissue Resource (NBTR), Newcastle University, UK in accordance with the approval of the joint Ethics Committee of Newcastle and North Tyneside Health Authority and following NBTR brain banking procedures. The neuropathological diagnosis was performed according to internationally accepted criteria [31] (Table 1). Tissue of one patient of Braak stage V/VI yielded clearly stronger pathology compared to the other cases, representing an overshoot outlier. Data of this patient were excluded for pThr231 calculations. For histological analyses, five cases per group were investigated using sections of 5 brain regions per individual: temporal cortex (TeCtx), frontal cortex (FrCtx), cingulate cortex (CiCtx), occipital cortex (OcCtx), and transentorhinal region (TEntR). All histological assessments were done blinded to clinical and neuropathological data.Table 1Individual case information. Demographic patient informationCaseAgeSexBraakstagePost mortem delay to fixation in hoursFixation time in weeksClinical information# on Western blotControls168M0547Cognitively normal1255M04111Cognitively normal2370M0726Cognitively normal–478F0348Cognitively normal4573M0259Cognitively normal–mean68.8045.28.2Braak I/II Low696F211449Mild dementia6777M28315Cognitively normal7894F2159Cognitively normal–970M2397Multiple psychiatric and physical problems91074F14910Cognitively normal10mean82.21.86018Braak III/IV Mod.1175M48223Cognitively normal111279M31315Cognitively normal121381M3828Unspecified dementia131498F3598Cognitively normal141591M3489Moderate cognitive impairment and vascular disease15mean84.83.256.812.6Braak V/VI High1684F64716Severe dementia, anxiety and depression–1777F6635Dementia171880F63216Dementia181986F656Dementia192089F6858Dementia–mean83.2646.410.2 Immunofluorescent labeling Sections were deparaffinized for 10 min in Tissue Clear (Sakura, 1466, Netherlands) and 5 min in Tissue Clear/100% ethanol, washed for 5 min in 100% ethanol and then subsequently rehydrated with decreasing alcohol concentrations (96, 70 and 50% ethanol for 2 min each). Thereafter, sections were washed twice for 5 min in PBS. Sections for labeling of human total tau, ThioflavinS (ThioS), pThr231 tau, pSer199 tau, pTyr18 tau and pSer396 tau were treated for 15 min with citrate buffer (Thermo Scientific, AP-9003) at 95 °C in a steamer and cooled down to room temperature (RT) for another 15 min. For ThioS staining, sections were then labeled with 0.5% ThioS (Sigma-Aldrich, T1892) for 7 min under light protection. Afterwards, sections were pretreated with ice-cold sodium borohydride/PBS solution (1 mg/ml; Sigma-Aldrich, 213,462) for 4 min and tissue was then permeabilized with 1% Triton® X-100/PBS (AppliChem, A1388) for 10 min. Non-specific labeling was blocked by incubating sections for 30–60 min either with 10% donkey serum/PBS or 10% horse serum/PBS. For antigen detection, sections were incubated with primary antibodies (Table 2) in a damp chamber. Primary antibody binding was visualized by incubating sections with secondary fluorophore conjugated antibodies (Table 3) for 60 min. Furthermore, cell nuclei of tissue labeled for pSer199 tau, pSer396 tau and pSer422 tau were visualized by counterstaining with 4′,6-Diamidin-2-phenylindol-working solution (DAPI,

Read the complete text